286 related articles for article (PubMed ID: 9158660)
1. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.
Ohtani K; Ninomiya H; Hasegawa Y; Kobayashi T; Kojima H; Nagasawa T; Abe T
Br J Haematol; 1995 Sep; 91(1):116-20. PubMed ID: 7577617
[TBL] [Abstract][Full Text] [Related]
3. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein.
Kyriakou D; Papadaki H; Eliopoulos AG; Foudoulakis A; Alexandrakis M; Eliopoulos GD
Int J Hematol; 1997 Oct; 66(3):367-71. PubMed ID: 9401283
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.
Pulkki K; Pelliniemi TT; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Br J Haematol; 1996 Feb; 92(2):370-4. PubMed ID: 8603002
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of determining serum soluble IL-6 receptor concentration in plasma cell dyscrasias].
Hou J; Zhao Y; Liu Y
Zhonghua Nei Ke Za Zhi; 1997; 36(2):94-6. PubMed ID: 9812567
[TBL] [Abstract][Full Text] [Related]
8. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma.
Kyrtsonis MC; Dedoussis G; Zervas C; Perifanis V; Baxevanis C; Stamatelou M; Maniatis A
Br J Haematol; 1996 May; 93(2):398-400. PubMed ID: 8639436
[TBL] [Abstract][Full Text] [Related]
9. Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study.
Kohsari M; Khadem-Ansari MH; Rasmi Y; Sayyadi H
Asian Pac J Cancer Prev; 2020 Jan; 21(1):127-132. PubMed ID: 31983174
[TBL] [Abstract][Full Text] [Related]
10. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
[TBL] [Abstract][Full Text] [Related]
11. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
12. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
13. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
14. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
16. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Minarík J; Zemanová M; Bacovský J; Heincová V;
Vnitr Lek; 2006 Mar; 52(3):232-40. PubMed ID: 16722154
[TBL] [Abstract][Full Text] [Related]
18. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
Toren A; Novick D; Or R; Ackerstein A; Slavin S; Nagler A
Transplantation; 1996 Jul; 62(1):138-42. PubMed ID: 8693533
[TBL] [Abstract][Full Text] [Related]
20. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.
Rawstron AC; Fenton JA; Ashcroft J; English A; Jones RA; Richards SJ; Pratt G; Owen R; Davies FE; Child JA; Jack AS; Morgan G
Blood; 2000 Dec; 96(12):3880-6. PubMed ID: 11090073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]